Opinions Jerome Hass
DRI Healthcare TrustDHT.UN.TOTOP PICKFeb 21, 2025
Jerome HassStock price when the opinion was issued
As of Jun 05, 2026. Market Open.
You might be interested:
A conservative way to invest in biotechs. Pays a good 3.5% yield and has a diverse portfolio of 28 royalties. Trades at 6x EV to EBITDA.
Jerome HassDHT offers a 3.58% yield and a relative cheap valuation. Its size adds some risk. Growth has been mixed, but 2026 is expected to see faster growth. Payout ratio is fairly low and the business is 'usually' stable. The distribution was last raised in November 2024. Debt is fairly high, as is common with the sector. We see it as OK for small cap income investors, but not altogether exciting. It is priced right, however.
Unlock Premium - Try 5i Free
(Note the short timeframe.) Trades at only 1.4x book value. Its 3 listed peers trade at 3.7x. Both PE and EV/EBITDA are at 6x.
Jerome Hass
Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. The royalty focus and the sector is interesting. The stock has done well following its public debut a month ago at $10. The company seems to be well managed and there is a good story and potential. Unlock Premium - Try 5i Free
Stockchase Insights
Applied similar royalty approach from mining sector to pharmaceutical business. Allows for new development in pharmaceutical business. Capital light business. Second listing in the world of this nature. Very cheap valuation, trading ~1.3x book value. Excellent long term prospects.